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Abstract: Background: Peptide radioligands may serve as radionuclide carriers to tumor sites
overexpressing their cognate receptor for diagnostic or therapeutic purposes. Treatment of mice with
the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic
stability and tumor uptake of biodegradable radiopeptides. Aiming to clinical translation of this
methodology, we herein investigated the impact of the approved pill Entresto, releasing the potent
NEP-inhibitor LBQ657 in vivo, on the stability and tumor uptake of two radiopeptides. Methods:
The metabolic stability of [99mTc]Tc-DB4 (DB4, N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-
His-Leu-Nle-NH2) and [111In]In-SG4 (SG4, DOTA-DGlu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2) was
tested in LBQ657/Entresto-treated mice vs. untreated controls. The uptake in gastrin-releasing peptide
receptor (GRPR)-, or cholecystokinin subtype 2 receptor (CCK2R)-positive tumors respectively, was
compared between LBQ657/Entresto-treated mice and untreated controls. Results: LBQ657/Entresto
treatment induced marked stabilization of [99mTc] Tc-DB4 and [111In]In-SG4 in peripheral mice blood,
resulting in equally enhanced tumor uptake at 4 h post-injection. Accordingly, the [99mTc]Tc-DB4
uptake of 7.13 ± 1.76%IA/g in PC-3 tumors increased to 16.17 ± 0.71/17.50 ± 3.70%IA/g (LBQ657/
Entresto) and the [111In]In-SG4 uptake of 3.07 ± 0.87%IA/g in A431-CCK2R(+) tumors to 8.11 ±
1.45/9.61 ± 1.70%IA/g. Findings were visualized by SPECT/CT. Conclusions: This study has shown
the efficacy of Entresto to notably improve the profile of [99mTc]Tc-DB4 and [111In]In-SG4 in mice,
paving the way for clinical translation of this approach.
Keywords: tumor-targeting; peptide radioligand; [99mTc]Tc-DB4; gastrin-releasing peptide receptor;
[111In]In-SG4; cholecystokinin subtype 2 receptor; single photon emission computed tomography;
neprilysin inhibition; Entresto; LBQ657; in vivo stability
1. Introduction
Latest advances in medicine have been aiming at personalized management of patients.
Toward this goal, modern anti-cancer drugs are being designed to specifically interact with
tumor-associated biomolecular targets, sparing healthy tissues devoid of target expression. For example,
peptide analogs may serve as radionuclide carriers to tumor-located receptors, allowing for
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diagnostic imaging and/or radionuclide cancer therapy—“cancer theranostics” [1–4]. Diagnostic
imaging may be performed by means of gamma emitters (e.g., technetium-99m, indium-111)
applying single photon emission tomography (SPECT) or via positron emitters (e.g., fluorine-18,
gallium-68, copper-64) in combination with positron emission tomography (PET). On the other
hand, particle emitters (e.g., lutetium-177, copper-67, actinium-225) accumulating on tumor
sites by suitably designed carriers will locally deliver cytotoxic payloads, eradicating tumor
lesions [5–7]. This approach has been successfully implemented in the clinic for neuroendocrine
tumor patients with the advent of theranostic somatostatin-based radioligands, such as the [68Ga]Ga-/
[177Lu]Lu-DOTA-TATE pair (DOTA-DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH, DOTA = 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) [8].
A major hurdle for a broader implementation of this method in nuclear oncology relates to
the notorious propensity of peptides to metabolic degradation. Enzymes hydrolyzing peptide
bonds, peptidases, rapidly catabolize radiopeptides entering the circulation, impairing radionuclide
delivery and uptake in pathological lesions. A typical way to increase the resistance of radiopeptides
to assaulting peptidases is through structural modifications of the peptide chain, such as amino
acid replacements, cyclization, reduction or methylation of peptide bonds and other means, which,
however, often negatively affect other important biological features, such as receptor affinity and
pharmacokinetics [9–11].
We have previously shown that the in vivo profile of linear radiopeptides originating from
either the bombesin (BBN, Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2), or the
minigastrin (MG, H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) peptide families,
and targeting the gastrin-releasing peptide receptor (GRPR) or the cholecystokinin subtype 2 receptor
(CCK2R) respectively, on tumors, are compromised primarily by the action of a single peptidase,
neprilysin (NEP) [12–14]. Most interestingly, we were able to show that co-injection of the NEP-inhibitor
phosphoramidon (PA) [15,16] induced significant stabilization of radiopeptides in peripheral blood,
thereby markedly enhancing tumor uptake in mice models [12,17–21]. This simple but effective
concept warrants validation in the clinic in view of the prospects it offers for a broader and more
effective application of radiopeptides in cancer theranostics. For such purposes, the availability of
NEP-inhibitors which are registered medicines and currently in clinical use is of great value [21].
In the present work, we decided to study the effects of such an approved NEP-inhibitor
firstly on the metabolic stability of two representative radiopeptide examples, (i) the BBN-based
[99mTc]Tc-DB4 (DB4, N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2) [22–24]
and (ii) [111In]In-SG4 (SG4, DOTA-DGlu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2) [20,24], generated from
truncated MG (Figure 1a,b). It should be noted that both [99mTc]Tc-DB4 [23] and [111In]In-MG11
(a Met11-derivative of [111In]In-SG4) have been previously clinically tested in a small number of
prostate cancer and medullary thyroid carcinoma patients [20,21,24,25]. As an approved NEP-inhibitor,
we selected sacubitrilat (LBQ657), which we administered in mice either intravenously together with
the radiopeptide, or per os via the registered pill Entresto, 30 min prior to radiopeptide injection,
closely mimicking a clinical setting. Entresto pills contain the LBQ657-precursor, sacubitril (AHU377),
and release the active substance LBQ657 after ester-hydrolysis by in vivo esterases (Figure 1c) [26–29].
Next, we compared the impact of treating the animals with either LBQ657 or Entresto vs. non-treated
control animals bearing subcutaneous tumors. In particular, for [99mTc]Tc-DB4, these treatments
were compared in mice bearing GRPR-positive human prostate adenocarcinoma PC-3 xenografts [30]
and for [111In]In-SG4, in mice bearing a double A431-CCK2R((+/−)) tumor model [31]. Conclusions
on the feasibility and efficacy of improving the tumor-targeting and pharmacokinetics of these two
representative radiopeptides with the aid of registered Entresto pills were drawn.
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Figure 1. Structure of (a) [99mTc]Tc-DB4, (b) [111In]In-SG4 and (c) sacubitril (AHU377) contained in 
Entresto pills and releasing the active substance sacubitrilat (LBQ657) in vivo upon ester-hydrolysis 
by esterases. Sacubitrilat is a potent and specific inhibitor of neprilysin (NEP). 
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DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) peptide conjugates (Figure 1) were 
provided by PiChem (Graz, Austria). [Tyr4]BBN (Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-
His-Leu-Met-NH2) was purchased from Bachem (Bubendorf, Switzerland). The neprilysin (NEP)-
inhibitor sacubitrilat (LBQ657, (2R,4S)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)-
pentanoic acid) was obtained from BIOMOL GmbH (Hamburg, Germany), while Entresto pills (200 
mg corresponding to 24 mg/26 mg sacubitril/valsartan per pill) containing the prodrug sacubitril 
(AHU377, 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4oxobutanoic 
acid) (Figure 1) (Novartis, Basel, Switzerland) were purchased from a local pharmacy. For animal 
treatment (vide infra), whole pills were ground to a fine powder in a mortar, divided and suspended 
in tab water to individual 12 mg/200 mL doses of pill per animal [32]. 
Technetium-99m in the form of [99mTc]NaTcO4 was collected by elution of a [99Mo]Mo/[99mTc]Tc 
generator (Ultra-Technekow™ V4 Generator, Curium Pharma, Petten, The Netherlands). Indium-111 
as an [111In]InCl3 solution was purchased from Curium Pharma (Petten, The Netherlands). 
esterases
. ( ) [99 , [1 I ]I -S 4 i il i i
ills and releasing the active substance sacubitrilat (LBQ657) in vi o upon est r-hydrolysis by
est rases. Sacubitrilat is a poten and specifi inh bitor of neprilysin (NEP).
2. Materials and Methods
2.1. Peptide Analogs—Inhibitors—Radioligands
2.1.1. Chemicals—Radionuclides
The DB4 (N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2, N4 = 6-(carboxy)-
1,4,8,11-tetraazaundecane) and SG4 (DOTA-DGlu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2, DOTA = 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) peptide conjugates (Figure 1) were provided by PiChem
(Graz, Austria). [Tyr4]BBN (Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) was
purchased from Bachem (Bubendorf, Switzerland). The neprilysin (NEP)-inhibitor sacubitrilat
(LBQ657, (2R,4S)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)-pentanoic acid) was
obtained from BIOMOL GmbH (Hamburg, Germany), while Entresto pills (200 mg corresponding
to 24 mg/26 mg sacubitril/valsartan per pill) containing the prodrug sacubitril (AHU377, 4-[[(2S,4R)-5-
ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4oxobutanoic acid) (Figure 1) (Novartis,
Basel, Switzerland) were purchased from a local pharmacy. For animal treatment (vide infra), whole
pills were ground to a fine powder in a mortar, divided and suspended in tab water to individual
12 mg/200 mL doses of pill per animal [32].
Technetium-99m in the form of [99mTc]NaTcO4 was collected by elution of a [99Mo]Mo/[99mTc]Tc
generator (Ultra-Technekow™ V4 Generator, Curium Pharma, Petten, The Netherlands). Indium-111
as an [111In]InCl3 solution was purchased from Curium Pharma (Petten, The Netherlands).
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2.1.2. Preparation of Radioligands
Lyophilized DB4 and SG4 were dissolved in HPLC-grade H2O to yield a 1 mM stock solution and
50 µL aliquots thereof were stored in Eppendorf Protein LoBind tubes at −20 ◦C.
Labeling of DB4 with technetium-99m was conducted in molar activities of 18–37 MBq/nmol in an
Eppendorf protein LoBind tube, wherein the following solutions were consecutively added: (i) 0.5 M
phosphate buffer pH 11.5 (50 µL), (ii) 0.1 M sodium citrate (5 µL), (iii) [99mTc]NaTcO4 generator eluate
(415 mL, 280–550 MBq), (iv) DB4 stock solution (15 µL, 15 nmol) and (v) freshly made SnCl2 solution in
EtOH (15 µg, 15 µL). After reaction for 30 min at ambient temperature, the pH was brought to ~7 by
adding 0.1 M HCl.
SG4 was labeled with indium-111 in molar activities of 3.7–7.4 MBq/nmol. Briefly, [111In]InCl3
(30 µL, in 50 mM HCl; corresponding to 11.1–22.2 MBq) was added to an Eppendorf protein LoBind
tube followed by the addition of SG4 (3 µL, 3 nmol) stock solution and 1 M sodium acetate buffer (3 µL,
pH 4.6). The labeling reaction mixture was incubated for 30 min at 85 ◦C. For quality control, a 2 µL
aliquot of the labeling solution was withdrawn and quenched with 28 µL of an acetate buffered solution
of diethylenetriaminepentaacetic acid (DTPA, 1 mM, pH 4.6). Finally, traces of free indium-111 in the
labelling solution were scavenged by addition of DTPA to a 1 mM final concentration. For small-animal
SPECT studies, the labelling reaction was performed with 150 µL of [111In]InCl3 solution (55–110 MBq)
and [111In]In-SG4 was isolated using a Symmetry Shield RP18 cartridge column (5 µm, 3.9 × 20 mm,
Waters, Eschborn, Germany). The column was eluted for 40 min with a linear gradient from 100%
A (15 mM ammonium acetate )/0% B (acetonitrile, MeCN) to 90% A/10% B in 5 min, then in 10 min
to 85% A/15% B, and afterwards, isocratic at 1 mL/min flow rate. [111In]In-SG4, tR = 28.4 min; SG4,
tR = 25.5 min; [111In]In-DTPA, tR = 1.1 min.
2.1.3. Quality Control
Reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on a Waters
Chromatograph based on a 600E multi-solvent delivery system coupled to a Waters 2998 photodiode
array detector (Waters, Vienna, Austria) and a Gabi gamma-detector (Raytest, RSM Analytische
Instrumente GmbH, Straubenhardt, Germany). Data processing and chromatography were controlled
by the Empower Software (Waters, Milford, MA, USA). For quality control, aliquots of the radiolabeling
solution were loaded on a Symmetry Shield RP18 cartridge column (5 µm, 3.9 × 20 mm, Waters,
Eschborn, Germany), eluted for 40 min with 0.1% trifluoroacetic acid (TFA) in H2O/MeCN applying a
linear gradient starting from 0% MeCN and a 2% increase per min at 1 mL/min flow rate (system 1).
Instant thin-layer chromatography (ITLC) analysis was additionally performed for [99mTc]Tc-DB4
on ITLC-SG strips (Pall Corporation, Port Washington, NY/USA), developed up to 10 cm from the
origin with 5 M ammonium acetate/MeOH 1/1 (v/v) for [99mTc]TcO2 × nH2O (Rf: 0; [99mTc]Tc-DB4
Rf: 0.8–1.0; [99mTc]TcO4– Rf: 0.8–1.0), or acetone for [99mTc]TcO4– detection (Rf: 1; [99mTc]Tc-DB4 and
[99mTc]TcO2 × nH2O Rf: 0). The radiochemical labeling yields exceeded 98% and the radiochemical
purity was >99%, and thus radioligands were used without further purification in all subsequent
experiments, with the exception of the SPECT/CT imaging experiment. Furthermore, samples of
[99mTc]Tc-DB4 and [111In]In-SG4 were tested before and after the end of all biological experiments to
monitor radiotracer integrity.
All manipulations with beta–- and gamma-emitting radionuclides and their solutions were
performed by trained and authorized personnel behind suitable shielding in licensed laboratories in
compliance with European radiation-safety guidelines and supervised by the Greek Atomic Energy
Commission (license # A/435/17092/2019).
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2.2. Biological Assays
2.2.1. Cell Culture
Human androgen-independent prostate adenocarcinoma PC-3 cells endogenously expressing
the GRPR [30] were obtained from LGC Standards GmbH (Wesel, Germany), whereas the
human epidermoid carcinoma A431 cell line transfected to stably express the human CCK2R
(A431-CCK2R(+)) [31,33] or devoid of CCK2R expression (A431-CCK2R(-)) was a gift from Prof. O.
Boerman (Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands) and Prof. L. Aloj (Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle
Ricerche, Naples, Italy). All culture reagents were obtained from Gibco BRL, Life Technologies (Grand
Island, NY, USA) or from Biochrom KG Seromed (Berlin, Germany).
Roswell Park Memorial Institute-1640 (RPMI-1640) medium with GlutaMAX-I and supplemented
with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin was used
for PC-3 cell culture. A431-CCK2R(+/−) cells were grown in Dulbecco’s Modified Eagle medium
(DMEM) with GlutaMAX-I, supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin
and 100 µg/mL streptomycin. In the case of A431-CCK2R(+) cells, the medium was additionally
supplemented with 250 µg/mL G418. Cells were kept in a controlled humidified air containing 5%
CO2 at 37 ◦C. Splitting of cells with a ratio of 1:2 to 1:5 was performed when approaching confluency
using a trypsin/ethylenediaminetetraacetic acid (EDTA) solution (0.05%/0.02% w/v).
2.2.2. Animal Studies
European guidelines were applied in all animal studies in supervised and licensed facilities (EL 25
BIO 021). The study protocols were approved by the Department of Agriculture and Veterinary Service
of the Prefecture of Athens (revised protocol number 1609 approved on 24 April 2019 for the stability
studies and revised protocol number 1610 approved on 24 April 2019 for biodistribution and imaging
studies). For stability experiments, 20 healthy male Swiss albino mice (30 ± 5 g, NCSR “Demokritos”
Animal House Facility) were used, divided in groups of 3 or 4 (vide infra). For biodistribution studies
with [99mTc]Tc-DB4, 16 female severe combined immune deficiency (SCID) mice (14.3 ± 1.3 g, six weeks
of age at the day of arrival, NCSR “Demokritos” Animal House Facility) were employed, divided in
4 groups of 4. Biodistribution and imaging studies with [111In]In-SG4 were conducted in 17 male SCID
mice (17.2 ± 3.0 g, six weeks of age at the day of arrival) from the same provider. 12 animals divided in
3 groups of 4 were used in biodistribution studies and 5 in SPECT/CT imaging.
2.2.3. In Vivo Stability Tests
A 100 µL bolus of [99mTc]Tc-DB4 (50–60 MBq, 3 nmol total peptide in vehicle: saline/EtOH 9/1 v/v)
or [111In]In-SG4 (11–22 MBq, 3 nmol of total peptide in saline/EtOH 9/1 v/v) was injected in the tail
vein of mice together with vehicle (100 µL; control; [99mTc]Tc-DB4, n = 3 or [111In]In-SG4, n = 4) or
with LBQ657 solution (100 µL injection solution containing 10 µg LBQ657, n = 3 for both analogs). In a
third set of animals per radioligand, mice received, by gavage, a single Entresto dose (12 mg/200 mL
per animal, prepared as described in Section 2.1.1.) 30 min prior to injection of either radiotracer
together with vehicle (100 µL; Entresto-group; [99mTc]Tc-DB4, n = 4 or [111In]In-SG4, n = 3). Mice were
euthanized 5 min after radioligand injection (5 min post-injection (pi)) and a prechilled syringe was
used to withdraw blood (0.5–1 mL) directly from the heart. Blood was transferred in a pre-chilled
EDTA-containing Eppendorf tube on ice and subsequently centrifuged for 10 min at 2000 g/4 ◦C.
The plasma was collected and an equal volume of ice-cold MeCN was added. The mixture was
centrifuged for 10 min at 15,000 g/4 ◦C. The supernatant was collected and a N2-flux at 40 ◦C was
applied to reduce the volume to 0.05–0.1 mL. After diluting with normal saline (0.4 mL), the solution
was passed through a 0.22 µm Millex GV filter (Millipore, Milford, USA). Filtrate aliquots were then
analyzed by radio-HPLC. A Symmetry Shield RP18 (5 µm, 3.9 × 20 mm) column served as stationary
phase, eluted at a flow rate of 1 mL/min by 0.1% TFA in H2O (A) and MeCN (B) combinations as mobile
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phase. In case of [99mTc]Tc-DB4, the following linear gradient system was applied: 0%B at 0 min, 10%B
at 10 min and reaching 25%B at 40 min (system 2a); for [111In]In-SG4, the gradient started with 0%B
increasing linearly with 1%/min to 40%B (system 2b). The tR of the intact radiopeptide was determined
by co-injection with the respective [99mTc]Tc-DB4 (tR = 31.5 min)/[111In]In-SG4 (tR = 30.0 min) reference
in the HPLC.
2.2.4. Tumor Induction in Mice
Aliquots of a suspension containing freshly harvested human PC-3 cells (≈1.2 × 107 cells in 150 µL
normal saline per mouse) were inoculated at the flanks of 16 female SCID mice and 3 weeks later,
well-palpable tumors (124 ± 35 mg) were grown at the inoculation sites. Inocula of A431-CCK2R(+)
and A431-CCK2R(−) cells (1.5 × 107 cells and 1.2 × 107 cells respectively, in 150 µL normal saline) were
subcutaneously injected in the right and left flanks respectively, of 12 male SCID mice; in 5 more mice,
a A431-CCK2R(+) cell suspension (1.5 × 107 cells in 150 µL normal saline) was subcutaneously injected
instead on the neck of the animals. Well-palpable tumors were developed in all cases after 10 days
(A431-CCK2R(+): 188 ± 56 mg; A431-CCK2R(−): 124 ± 49 mg). All animals were kept under aseptic
conditions during this period and until biodistribution or imaging was conducted.
2.2.5. Biodistribution of [99mTc]Tc-DB4 and [111In]In-SG4 in Tumor-Bearing Mice
For the biodistribution study, animals in groups of 4 received a 100µL bolus of [99mTc]Tc-DB4 via the
tail vein (200 kBq, corresponding to 10 pmol total peptide in saline/EtOH 9/1 v/v—GRPR-tumor-bearing
mice) or [111In]In-SG4 (50 kBq, 10 pmol total peptide—twin A431-CCK2R(+)/A431-CCK2R(−)
tumor-bearing mice) co-injected either with injection solution (100 µL; control) or with LBQ657
solution (100 µL injection solution containing 10 µg LBQ657). In additional sets of animals, mice
received, by gavage, a single Entresto dose (12 mg/200 mL per animal, prepared as described in
Section 2.1.1) 30 min prior to injection of the respective radiotracer together with vehicle (100 µL;
Entresto group), or with a [Tyr4]BBN solution (100 µg in 100 µL vehicle; block group). Mice were
euthanized at 4 h pi and dissected. Samples of blood, tumors and organs of interest were collected,
weighed and measured for radioactivity in the γ-counter (an automated well-type gamma counter
with a NaI(Tl) 3′’ crystal, Canberra Packard Auto-Gamma 5000 series instrument). Intestines and
stomach were not emptied of their contents; exceptionally, in the case of [111In]In-SG4-injected animals,
stomachs were emptied of their contents. Data was calculated as percent injected activity per gram
tissue (%IA/g) with the aid of standard solutions and represented as mean values ± standard deviation
(SD), n = 4.
2.2.6. Statistical Analysis
The two-way analysis of variance (ANOVA) with multiple comparisons was used for statistical
analysis of biological results, applying Tukey’s post hoc analysis (GraphPad Prism Software 6, San Diego,
CA, USA). p-values below 0.05 were considered to be statistically significant.
2.2.7. SPECT/CT Imaging of [111In]In-SG4 in A431-CCK2R(+) Tumor-Bearing Mice
Five mice bearing A431-CCK2R(+) xenografts on their shoulders were used for SPECT/CT imaging.
Three out of five mice received Entresto by gavage 30 min prior to radiotracer injection. All five animals
were injected with a bolus containing [111In]In-SG4 (100 µL, 5 MBq of HPLC isolated preparation)
via the tail vein and were euthanized 4 h later. The y-CUBE/x-CUBE systems (Molecubes, Belgium)
were employed for tomographic SPECT/CT imaging [34]. The SPECT system was based on monolithic
NaI detectors attached to SiPMs, with a 0.6 mm intrinsic resolution. The CT system was based on a
structured CMOS detector of CsI with pixels of 75 µm and operated between 35 and 80 kVp, 10–500 µA
tube current, with a 33 µm fixed focal spot size. For SPECT scans, a 60 min duration protocol was
applied, based on the injected activity. A CT scan followed after each SPECT scan, according to a
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General Purpose protocol under 50 kVp for co-registration purposes. The MLEM reconstruction
method was applied for the reconstruction of SPECT images with a 250 µm voxel size and 500 iterations.
The ISRA reconstruction method with a 100 µm voxel size was applied for the reconstruction of CT
images. Images were exported and post-processed on VivoQuant software, version 4.0 (Invicro, Boston,
MA, USA). A smoothing median filter (0.6 mm, spherical window) was applied to the images and for
consistency purposes, the bladder was removed.
3. Results
3.1. Peptides and Radioligands
Labeling of DB4 with technetium-99m typically proceeded by brief peptide-conjugate incubation
with [99mTc]TcO4– generator eluate, SnCl2 as reducing agent and citrate anions as transfer ligand in
alkaline pH at ambient temperature at molecular activities of 18–37 MBq [99mTc]Tc/nmol peptide.
Labeling of SG4 with indium-111 was accomplished by 30 min incubation of the peptide-conjugate
at 85 ◦C with [111In]InCl3 in acidic medium at molecular activities 3.7 × 7.4 MBq [111In]In/nmol
peptide. Quality control of the radiolabeled products combined HPLC and ITLC analysis. The total
radiochemical impurities in the case of [99mTc]Tc-DB4, comprising [99mTc]TcO4–, [99mTc]Tc-citrate
and [99mTc]TcO2 nH2O, did not exceed 2%, while a single radiopeptide species was detected by
RP-HPLC. Likewise, labeling yields above 98% and radiochemical purity above 99% were confirmed
for [111In]In-SG4 during HPLC analysis. Therefore, the radioligands were used without further
purification in all subsequent experiments, except for imaging (vide infra).
3.2. In Vivo Studies
3.2.1. Stability of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice
Both radiotracers were catabolized to a great extent 5 min after their entry in mice circulation.
As revealed by HPLC analysis of blood samples collected at 5 min pi (Figure 2a), only 26.9% ± 3.7%
[99mTc]Tc-DB4 was found intact in peripheral mice blood in this period (Figure 2b). Co-injection of
LBQ657 led to notable stabilization of the radiotracer (74.3% ± 8.6% intact; p < 0.0001), whereas a
similar stabilization effect was observed in mice treated with Entresto 30 min prior to radioligand
injection (71.5% ± 1.8% intact; p < 0.0001). A summary of these results in numerical values is included
in Table 1.
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(a) (b) 
Figure 2. (a) Representative radiochromatograms of PL analysis (HPLC system 2a) of mice blood
samples collected 5 min pi of [99mTc]Tc-DB4, co-injected with vehicle (green line), LBQ657 (blue line) or
co-injected with vehicle 30 min after oral administration of Entresto (red line). (b) Comparison of percent
intact [99mTc]Tc-DB4 across treatments (green, blue and red bars, respectively), showing statistically
significant differences between LBQ657- or Entresto-treated mice vs. controls (**** p < 0.0001).
Numerical average values ± standard deviation (SD) are summarized in Table 1.
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Table 1. Stabilities of [99mTc]Tc-DB4 and [111In]In-SG4 in peripheral mouse blood 5 min pi.
Treatment [99mTc]Tc-DB4 [111In]In-SG4
Control 26.9 ± 3.7 (n = 3) 11.5 ± 3.2 (n = 4)
LBQ 74.4 ± 8.6 (n = 3) 72.7 ± 2.4 (n = 3)
Entresto 71.5 ± 1.8 (n = 4) 78.0 ± 2.7 (n = 3)
Data represents the mean percentage of intact radioligand ± SD; n of experiments are shown in parentheses.
Likewise, HPLC analysis of blood samples collected at 5 min pi of [111In]In-SG4 (Figure 3a)
revealed only 11.5% ± 3.2% intact radiotracer (Figure 3b).
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3.2.2. Biodistribution of [99mTc]Tc-DB4 SCID ice Bearing PC-3 Xenografts
The biodistribution of [99mTc]Tc-DB4 at 4 h pi was studied in SCID mice bearing subcutaneous
PC-3 tumors expressing the human GRPR, without or during treatment with LBQ657 or Entresto.
Biodistribution data, expressed as mean %IA/g ± SD, n = 4, is summarized in Table 2. The radiotracer
has washed out from the blood and the body of mice predominantly via the kidneys and the urinary
system, with some degree of intestinal uptake. High uptake is seen in the GRPR-rich pancreas
(27.71 ± 6.36%IA/g) as well as in the implanted tumors (7.13 ± 1.76%IA/g).
Co-injection of LBQ657 or treatment of mice with Entresto resulted in clear enhancement of
tumor uptake (to 16.17 ± 0.71%IA/g; p < 0.0001 and to 17.50 ± 3.70%IA/g; p < 0.0001 respectively, vs.
controls). No significant increase was observed in any other organ or tissue, except for the pancreas.
In this case, the radioligand stabilization by either LBQ657 or Entresto led to significant increases of
pancreatic uptake in the mice (to 56.06 ± 4.24%IA/g; p < 0.0001 and to 60.98 ± 6.41%IA/g; p < 0.0001
respectively, vs. controls). It should be noted that uptake in the tumors as well as in pancreas and
in mice intestines was significantly reduced in mice co-injected with excess [Tyr4]BBN 30 min after
treatment with Entresto, revealing a GRPR-mediated process (to 0.55 ± 0.04%IA/g; p < 0.0001, to 0.68 ±
0.04%IA/g; p < 0.0001 and to 1.23 ± 0.21%IA/g; p < 0.01 respectively, vs. the Entresto group).
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Table 2. Biodistribution data for [99mTc]Tc-DB4, expressed as %IA/g mean ± SD, n = 4, in PC-3
xenograft-bearing SCID mice at 4 h pi without or during treatment with either LBQ657 or Entresto.
Tissue
[99mTc]Tc-DB4—4 h pi
Controls 1 LBQ657 2 Entresto 3 Block 4
Blood 0.12 ± 0.11 0.14 ± 0.03 0.17 ± 0.03 0.08 ± 0.01
Liver 1.76 ± 0.74 1.61 ± 0.19 1.27 ± 0.20 0.90 ± 0.10
Heart 0.24 ± 0.13 0.26 ± 0.03 0.23 ± 0.07 0.13 ± 0.00
Kidneys 9.56 ± 4.35 4.67 ± 1.03 7.86 ± 2.46 4.72 ± 0.72
Stomach 1.50 ± 0.71 1.12 ± 0.20 1.66 ± 0.30 0.20 ± 0.04
Intestines 7.99 ± 0.08 9.00 ± 0.64 11.36 ± 0.95 1.23 ± 0.21
Spleen 1.92 ± 0.75 2.46 ± 0.95 1.93 ± 0.44 2.60 ± 0.48
Muscle 0.06 ± 0.02 0.06 ± 0.01 0.10 ± 0.09 0.03 ± 0.00
Lungs 0.40 ± 0.21 0.52 ± 0.18 0.66 ± 0.11 0.72 ± 0.26
Pancreas 27.71 ± 6.36 56.06 ± 4.24 60.98 ± 6.41 0.68 ± 0.04
Tumor 7.13 ± 1.76 16.17 ± 0.71 17.50 ± 3.70 0.55 ± 0.04
All animals were injected with 200 kBq/10 pmol peptide. 1 Mice co-injected with vehicle, 2 mice co-injected with
LBQ657, 3 mice co-injected with vehicle 30 min after oral administration of Entresto and 4 mice co-injected with
[Tyr4]BBN 30 min after oral administration of Entresto for in vivo GRPR-blockade.
3.2.3. Biodistribution of [111In]In-SG4 in SCID Mice Bearing Twin A431-CCK2R((+/−)) Xenografts
The biodistribution of [111In]In-SG4 at 4 h pi was studied in SCID mice bearing subcutaneous double
A431-CCK2R((+/−)) tumors, without or during treatment with LBQ657 or Entresto. Biodistribution
data is summarized in Table 3, expressed as mean %IA/g ± SD, n = 4.
Table 3. Biodistribution data for [111In]In-SG4 at 4 h pi, expressed as %IA/g mean ± SD, n = 4, in SCID
mice bearing double A431-CCK2R(+/−) xenografts without or during treatment with either LBQ657
or Entresto.
Tissue
[111In]In-SG4—4 h pi
Controls 1 LBQ657 2 Entresto 3
Blood 0.03 ± 0.02 0.07 ± 0.01 0.06 ± 0.01
Liver 0.15 ± 0.02 0.24 ± 0.02 0.23 ± 0.03
Heart 0.05 ± 0.02 0.07 ± 0.01 0.10 ± 0.01
Kidneys 2.10 ± 0.49 2.39 ± 0.11 2.40 ± 0.61
Stomach 1.29 ± 0.25 3.10 ± 0.41 2.86 ± 0.53
Intestines 0.46 ± 0.05 0.49 ± 0.12 0.34 ± 0.07
Spleen 0.11 ± 0.04 0.23 ± 0.06 0.22 ± 0.05
Muscle 0.03 ± 0.02 0.07 ± 0.02 0.05 ± 0.01
Lungs 0.06 ± 0.01 0.10 ± 0.01 0.11 ± 0.01
Pancreas 0.08 ± 0.09 0.31 ± 0.01 0.34 ± 0.14
Femur 0.10 ± 0.03 0.13 ± 0.01 0.14 ± 0.03
Tumor (+) 3.07 ± 0.87 8.11 ± 1.45 9.61 ± 1.70
Tumor (–) 0.28 ± 0.21 0.28 ± 0.01 0.40 ± 0.23
All animals were injected with 50 kBq/10 pmol peptide. 1 Mice co-injected with vehicle, 2 mice co-injected with
LBQ657 and 3 mice co-injected with vehicle 30 min after oral administration of Entresto.
The uptake of [111In]In-SG4 significantly increased only in the A431-CCK2R(+) xenografts after
treatment of mice with either LBQ657 (from 3.07 ± 0.87%IA/g to 8.11 ± 1.45%IA/g; p < 0.0001) or
Entresto (from 3.07 ± 0.87%IA/g to 9.61 ± 1.70%IA/g; p < 0.0001), but not in the A431-CCK2R(−) tumors,
suggesting CCK2R-specificity. Non-significant changes were observed in all other tissues, except for
the CCK2R-positive stomach, showing higher uptake during treatment with LBQ657 (from 1.29 ±
0.25%IA/g to 3.10 ± 0.41%IA/g; p < 0.001) or Entresto (from 1.29 ± 0.25%IA/g to 2.86 ± 0.53%IA/g;
p < 0.01).
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Cumulative data on the impact of LBQ657 and Entresto on the uptake of [99mTc]Tc-DB4 and
[111In]In-SG4 on PC-3 and A431-CCK2R(+) xenografts respectively, is presented in Figure 4.
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Figure 4. Comparative uptake at 4 h pi (as mean %IA/g values ± SD, n= 4) of (a) [99mTc]Tc-DB4 in PC-
3 GRPR-expressing xenografts without (green bars) or during treatment of mice with either LBQ657 
(blue bars) or Entresto (red bars), and (b) [111In]In-SG4 in A431-CCK2R(+) xenografts without (green 
bars) or during treatment of mice with either LBQ657 (blue bars) or Entresto (red bars). Statistically 
significant differences were observed for both radioligands between mice treated with either NEP-
inhibitor vs. controls (*** p < 0.001, **** p < 0.0001), but not between the LBQ657 and Entresto groups 
(p > 0.05). 
3.2.4. SPECT/CT of [111In]In-SG4 in A431-CCK2R(+) Xenograft-Bearing Mice 
Mice SPECT/CT images obtained 4 h after injection of [111In]In-SG4 are presented in Figure 5. 
Significant accumulation was achieved in the CCK2R-expressing A431-CCK2R(+) xenografts, while 
much lower radioactivity levels remained in the kidneys. Clear differences in tumor uptake could be 
observed between controls (Figure 5a,b) and Entresto-treated mice (Figure 5c–e), in line with 
biodistribution findings. 
Figure 4. Comparative uptake at 4 h pi (as mean %IA/g values ± SD, n= 4) of (a) [99mTc]Tc-DB4 in PC-3
GRP -expressing xenografts without (green bars) o du ing treatm n of mice with either LBQ657 (blue
bars) or Entresto (red bars), and (b) [111In]In-SG4 in A431-CCK2R(+) xenografts without (green bars) or
during treatment of mic with either LBQ657 (blue bars) or Entresto ( ed bar ). Statistically signifi nt
differences wer obs rved for oth radi ligands between mice reated with eith r NEP-inhibitor vs.
controls (*** p < 0.001, **** 0.0001), but not between the LBQ657 and Entresto groups (p > 0.05).
3.2.4. SPECT/CT of [111In]In-SG4 in A431-CCK2R(+) Xenograft-Bearing Mice
Mice SPE T/CT images obtained 4 h after injection of [111In]I -SG4 are presented in Figure 5.
Significant accumulation was achieved in the CCK2R-expressing A431-CCK2R(+) xenografts, while
much lower radioactivity levels remained in the kidneys. Clear differences in tumor uptake could
be observed between controls (Figure 5a,b) and Entresto-treated mice (Figure 5c–e), in line with
biodistribution findings.Pharmaceutics 2020, 12, x FOR PEER REVIEW 11 of 14 
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commercially available recently as an antihypertensive drug [26–28]. Entresto pills for oral 
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Figure 5. Static whole-body SPECT/CT images of five SCID mice bearing A431-CCK2R(+) tumors 4 h
after injection of [111In]In-SG4 (a,b) without, or (c–e) with pre-treatment with Entresto, received orally
30 in in advance. Intense uptake is seen on tumor (green arrows), with kidneys showing only weakly
in comparison (turquois arrows). A notable increase in the tumor uptake has resulted after treatment of
mice with Entresto (c–e) versus controls (a,b). The color bar indicates the difference in accumulated
activity (purple being the lowest and white the highest level of accumulation).
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4. Discussion
A major challenge in a wider application of peptide radioligands in cancer theranostics is linked
to their fast catabolism in the biological milieu by peptidases [10,11]. We have previously reported on
the prominent role of NEP in the rapid in vivo degradation of radioligands originating from various
peptide families, including bombesin and gastrin [12]. NEP is an ectoenzyme with a broad substrate
repertoire anchored on epithelial cell membranes of blood vessels and major organs of the body in
high local concentrations [13,14]. A great number of radiopeptide analogs entering the circulation
become exposed to its action and get swiftly degraded, with only a fraction of the original number
of molecules reaching the tumor-associated receptors intact. As a result, diagnostic contrast and/or
therapeutic efficacy are strongly compromised. We were able to successfully interfere with this chain
of disadvantageous events by inducing transient NEP-inhibition through co-injection of PA [15,16] in
mice. As a result, marked increases in the metabolic stability of various circulating peptide radiotracers
could be achieved, directly favoring tumor uptake [12,17–21,24]. These exciting results, documented
at the preclinical level in a multitude of cases, warrant further validation in cancer patients. Clinical
proof of this concept may promptly enrich the arsenal of anti-cancer theranostic tools, since the profiles
of available radiopeptides can be optimized in situ. In this way, time-/cost-intensive structure–activity
relationship studies with the development of new radiotracer libraries may be circumvented.
Toward this goal, we have decided to explore the efficacy of approved NEP-inhibitors that
could replace PA in a clinical setting [21,25]. Most interestingly, Entresto was approved and
became commercially available recently as an antihypertensive drug [26–28]. Entresto pills for
oral administration contain a combination of valsartan and sacubitril. The latter is the precursor
form of the potent NEP-inhibitor sacubitrilat (LBQ657) [29], which is quickly released in vivo via
de-esterification by endogenous esterases (Figure 1c). In the present work, we were interested to study
the effects of both Entresto and the active substance LBQ657 on the stability and biodistribution profile
of two radiopeptide examples, [99mTc]Tc-DB4 and [111In]In-SG4 (Figure 1a, b, respectively). LBQ657
was intravenously injected in mice together with either radioligand. The pill was orally administered
30 min in advance of radiotracer injection, so as to accomplish similar levels of the active substance in
mice plasma and hence similar NEP-inhibition efficacy [32].
As depicted in Figures 2 and 3, neither of the two radiotracers were detected intact in peripheral
mice blood in the absence of inhibitors as soon as 5 min pi, revealing a very rapid action of native
peptidases. Co-injection of the NEP-inhibitor significantly increased the metabolic stability of
both radiopeptides, directly implicating NEP in their swift in vivo degradation. Most interestingly,
treatment of mice with the pill induced the same stabilization levels of the radiotracers, confirming the
indistinguishable efficacy of Entresto and LBQ657 to inhibit NEP in situ [29,32]. It should be noted
that PA was previously shown to stabilize BBN-/MG-based radiotracers, including [111In]In-SG4, with
comparable efficacy [12].
We next investigated how the aforementioned radioligand stabilization affected tumor targeting
and overall pharmacokinetics of the two radioligands. As shown in Table 2, we could observe a
highly significant increase in the uptake of [99mTc]Tc-DB4 in the PC-3 xenografts at 4 h pi in both
Entresto- and LBQ657-treated mice compared with untreated controls, with the two treatments being
equally effective. It should be noted that in the “block” animal group, whereby mice were treated with
Entresto and a high excess of [Tyr4]BBN, tumor uptake was minimized. This finding is suggestive of
GRPR-specificity, ruling out GRPR-unrelated interferences of the pill in the observed tumor uptake
enhancement. Additional increases of radioactivity levels could be observed in mice pancreas and
intestines. Such increases could be attributed to the known physiological expression of GRPR in
the healthy organs, as implied by the respective values in the “block” animal group. Again, similar
observations were previously reported for most BBN-based radioagonists after treatment of mice with
PA [12,17–19,35].
The impact of treating mice with Entresto and LBQ657 on the uptake of [111In]In-SG4 in the
A431-CCK2R(+) xenografts compared with untreated controls is summarized in Table 3. Again,
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the stabilization of the radiotracer in peripheral mice blood by either Entresto or LBQ657 led to
significant and comparable increases in the CCK2R-expressing tumors compared with untreated
controls. Furthermore, the observed enhancements were apparent only in the A431-CCK2R(+), but
not in the A431-CCK2R(−) xenografts, suggesting CCK2R-specificity. Similar enhancements could be
induced previously by transient NEP-inhibition by PA [12,20,21,24]. In view of the fact that background
radioactivity levels remained the same between the Entresto and the control animal groups, including
the mice CCK2R-rich gastric mucosa, we further proceeded to visualize these effects by SPECT/CT.
As shown in the representative images of Figure 5 taken 4 h pi of [111In]In-SG4, a striking increase of
tumor uptake could be established in the Entresto-treated mice group over the non-treated controls.
5. Conclusions
This study has shown that Entresto, an approved antihypertensive pill to be taken orally and
promptly releasing the potent NEP-inhibitor LBQ657 in vivo [29], can induce comparable stabilization
effects with LBQ657 and the non-licensed NEP-inhibitor PA of GRPR-/CCK2R-directed radiopeptides.
The observed stabilization was shown to drastically improve the uptake of two representative
radiopeptides, [99mTc]Tc-DB4 and [111In]In-SG4, in tumor-bearing mice via GRPR-/CCK2R-specific
pathways, most probably by enhancing the supply of intact radiotracers to tumor-residing receptors.
These findings represent an important further step for the proof-of-principle of this approach in cancer
patients and may thus contribute in a broader and more effective application of radiopeptides in
nuclear oncology.
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